Suspension of trading
Valuation iTeos Therapeutics, Inc.
Stocks
ITOS
US46565G1040
Biotechnology & Medical Research
|
Delayed
Nasdaq
00:00:00 29/08/2025 +04
|
5-day change | 1st Jan Change | ||
| 10.15 USD | +0.20% |
|
-.--% | - |
| 03/09/25 | Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel | CI |
| 01/09/25 | ITeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from NASDAQ Composite Index | CI |
Company Valuation: iTeos Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Market Cap 1 | 1,185 | 1,642 | 694.8 | 391.8 | 280.6 |
| Change | - | 38.57% | -57.7% | -43.6% | -28.4% |
| Enterprise Value (EV) 1 | 848.9 | 799.2 | 86.3 | -134 | -209 |
| Change | - | -5.86% | -89.2% | -255.29% | -55.93% |
| P/E | -11.8x | 8.2x | 7.63x | -3.48x | -2.31x |
| PBR | 3.67x | 2.99x | 1.05x | 0.68x | 0.48x |
| PEG | 0.1x | -0x | -0.1x | 0x | -0.43x |
| Capitalization / Revenue | - | 4,763,549x | 2,596,069x | 31,111,178x | 8,016,585x |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -19.1x | 3.26x | 0.67x | 0.91x | 1.34x |
| EV / EBIT | -18.9x | 3.26x | 0.68x | 0.91x | 1.33x |
| EV / FCF | -45.1x | 1.85x | -0.58x | 1.83x | 3.25x |
| FCF Yield | -2.22% | 54% | -174% | 54.7% | 30.8% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -2.878 | 5.68 | 2.56 | -3.15 | -3.321 |
| Distribution rate | - | - | - | - | - |
| Net sales | - | 344.8 | 267.6 | 12.6 | 35 |
| EBITDA 1 | -44.42 | 245.5 | 128.3 | -146.7 | -155.6 |
| EBIT 1 | -44.95 | 244.9 | 127.5 | -147.6 | -156.8 |
| Net income 1 | -38.03 | 214.5 | 96.65 | -112.6 | -134.4 |
| Net Debt 1 | -336.3 | -843.2 | -608.5 | -525.9 | -489.6 |
| Reference price 2 | 33.82 | 46.56 | 19.53 | 10.95 | 7.68 |
| Nbr of stocks (in thousands) | 35,045 | 35,274 | 35,575 | 35,785 | 36,534 |
| Announcement Date | 24/03/21 | 23/03/22 | 15/03/23 | 06/03/24 | 05/03/25 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 449M | |
| 21.09x | 7.5x | 15.07x | 1.41% | 72.26B | |
| 31.3x | 9.02x | 28.11x | 0.04% | 60.24B | |
| 32.1x | 6.85x | 17.78x | -.--% | 27.73B | |
| -72.3x | 13.87x | -75.56x | -.--% | 25.73B | |
| -15.17x | 5.73x | -7.2x | -.--% | 24.75B | |
| 28.46x | 5.35x | 17.81x | -.--% | 20.74B | |
| 42.74x | 15.97x | 32.4x | 0.35% | 15.06B | |
| 17.96x | 5.35x | 12.5x | -.--% | 14.41B | |
| 1015.79x | 35.53x | 613.78x | -.--% | 14.23B | |
| Average | 122.44x | 11.69x | 72.74x | 0.2% | 27.56B | |
| Weighted average by Cap. | 65.46x | 9.84x | 39.70x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ITOS Stock
- Valuation iTeos Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
